| Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia. | |
| | |
MedLine Citation:
|
PMID: 10073375 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A valid and compelling cost-effectiveness analysis of psychopharmacologic treatment of schizophrenia requires the application of analytically rigorous methods. All cost-effectiveness analyses must consider the issue of perspective as the well as the appropriate measurement of benefits and costs. Many of these issues are particularly difficult to address in the case of schizophrenia. Since costs may be borne by a wide range of parties, the choice of perspective is of critical importance. The fact that treatments for schizophrenia can extend life and the complexities raised by taking a broad perspective on the benefits and costs of treating schizophrenia can create challenges in the measurement of both benefits and costs. The measurement of benefits through quality-adjusted life years is also crucial in demonstrating the cost-effectiveness of treatments for schizophrenia, but is challenging because of the difficulty of measuring quality of life in schizophrenic patients. Attention to these important methodological issues is essential if cost-effectiveness analyses are to be useful in shepherding scarce resources to worthwhile treatments for patients with schizophrenia. |
| | |
Authors:
|
D Meltzer |
Related Documents
:
|
8476155 - Comparison of continuous single layer polypropylene anastomosis with double layer and s... 15943705 - Cost-effectiveness of leucocyte-depleted erythrocyte transfusion in cardiac valve surgery. 16186435 - Is duplex surveillance of value after leg vein bypass grafting? principal results of th... 11866675 - Pharmacoeconomics of drug therapy for atopic dermatitis. 20846225 - Mediating roles of social support on poststroke depression and quality of life in patie... 16143175 - The role of vestibular rehabilitation in the treatment of meniere's disease. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Journal of clinical psychiatry Volume: 60 Suppl 3 ISSN: 0160-6689 ISO Abbreviation: J Clin Psychiatry Publication Date: 1999 |
Date Detail:
|
Created Date: 1999-03-15 Completed Date: 1999-03-15 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 7801243 Medline TA: J Clin Psychiatry Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 32-5; discussion 36-7 Citation Subset: IM |
Affiliation:
|
Department of Medicine, University of Chicago, Ill 60637, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Ambulatory Care
/
economics Antipsychotic Agents / economics*, therapeutic use* Cost of Illness Cost-Benefit Analysis Drug Costs Family Health Health Care Costs Hospitalization / economics Humans Schizophrenia / drug therapy*, economics* |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The Wisconsin Quality of Life Index: a multidimensional model for measuring quality of life.
Next Document: What about the patient?